Samuel S Simons, Jr

Title: Samuel S. Simons, Jr.: Innovator in Glucocorticoid Receptors

Introduction: Samuel S. Simons, Jr. is a notable inventor based in Bethesda, MD (US). He has made significant contributions to the field of biochemistry, particularly in the development of glucocorticoid receptors. His innovative work has led to advancements in understanding how these receptors function and their potential applications in medicine.

Latest Patents: Samuel S. Simons, Jr. holds a patent for "Super glucocorticoid receptors: receptors with increased affinity." This invention relates to novel glucocorticoid receptors that exhibit greater affinity and specificity for glucocorticoid steroids compared to naturally occurring receptors. The patent details the alteration of cysteine-656 of the rat glucocorticoid receptor to either serine or glycine, resulting in super glucocorticoid receptors that maintain full biological activity in intact cells. These receptors have higher affinity and specificity for glucocorticoid steroid binding than the original receptor. The invention also encompasses the recombinant expression of these altered receptors in host cells.

Career Highlights: Samuel S. Simons, Jr. is associated with the United States of America as represented by the Department of Health. His work has been pivotal in advancing the understanding of glucocorticoid receptors and their applications in therapeutic contexts.

Collaborations: Samuel has collaborated with notable colleagues, including Pradip K. Chakraborti and Keith R. Yamamoto. Their combined expertise has contributed to the success of their research endeavors.

Conclusion: Samuel S. Simons, Jr. is a distinguished inventor whose work on super glucocorticoid receptors has the potential to impact medical science significantly. His innovative contributions continue to pave the way for advancements in biochemistry and therapeutic applications.